Announcement on Preliminary Earnings Estimate for 2025
Filed with SSE · · 3 pages · Chinese
Kexing Biopharm Co., Ltd. on 6ix
Earlier from Kexing Biopharm
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GB19 Injection
- Announcement on Progress in Repurchasing Shares through Call Auction
- Earnings Preannouncement for 2025
- Announcement on Estimated Amount of Daily Related Transactions in 2026
- Announcement on Renewing Engagement of Accounting Firm
Later from Kexing Biopharm
- Announcement on Signing Daily Related Party Transaction Agreements
- Announcement on Progress and Implementation Result of Shares Repurchase and Share Changes
- Announcement on Opening a Special Account for Raised Funds and Signing a Tripartite Supervision Agreement on Special Account Deposit of Raised Funds
- Announcement on Voluntary Disclosure of GB19 Injection Obtaining FDA Clinical Trial Approval for New Drugs
- 2025 Annual Report
Follow Kexing Biopharm into a list and get an email when it puts out news.
Follow Kexing Biopharm